FDA Panel Will Review Cardiac Resynch ICD For Mortality Reduction Claim
This article was originally published in The Gray Sheet
Executive Summary
An expanded labeling proposal facing FDA Circulatory System Devices Panel review July 28 would claim a 36% risk reduction in all-cause mortality for patients with Guidant's cardiac resynchronization therapy defibrillator (CRT-D)